Novo Nordisk has announced positive results from a Phase 3 clinical trial evaluating CagriSema for the treatment of non-alcoholic steatohepatitis (NASH), according to findings published in The New England Journal of Medicine. CagriSema is an investigational combination therapy that pairs cagrilintide, an amylin analog, with semaglutide, a GLP-1 receptor agonist already marketed as Wegovy and Ozempic. The trial data suggests this dual-action approach may offer significant benefits for patients with this progressive liver disease.
NASH, characterized by fat accumulation and inflammation in the liver, affects an estimated 3-5% of the global population and can progress to cirrhosis and liver failure. The condition is closely linked to obesity and type 2 diabetes, making metabolic interventions a logical therapeutic target. Currently, no pharmacological treatments have received full regulatory approval specifically for NASH, representing a substantial unmet medical need in hepatology.
The combination of GLP-1 receptor agonism with amylin analog activity offers a novel mechanistic approach to addressing NASH. While semaglutide promotes weight loss and improves glycemic control, cagrilintide works by slowing gastric emptying and reducing appetite through different pathways. This dual mechanism may provide enhanced metabolic benefits compared to either agent alone, potentially addressing both the underlying metabolic dysfunction and liver-specific pathology in NASH patients.
These Phase 3 results position Novo Nordisk competitively in the race to develop effective NASH therapies, joining other pharmaceutical companies pursuing treatments for this indication. For patients living with NASH, the positive trial outcomes offer hope for a future evidence-based treatment option. The findings also underscore the expanding therapeutic applications of GLP-1-based medications beyond diabetes and obesity management, potentially opening new avenues for metabolic liver disease treatment in clinical practice.
